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Comparison of the Eragen Multi-Code Respiratory Virus Panel with
Conventional Viral Testing and Real-Time Multiplex PCR
Assays for Detection of Respiratory Viruses䌤†
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Pediatrics, School of Medicine and Public Health, University of Wisconsin—Madison, Madison, Wisconsin3
Received 3 February 2010/Returned for modification 15 March 2010/Accepted 7 May 2010

High-throughput multiplex assays for respiratory viruses are an important step forward in diagnostic
virology. We compared one such assay, the PLx Multi-Code Respiratory Virus Panel (PLx-RVP), manufactured
by Eragen Biosciences, Inc. (Madison, WI), with conventional virologic testing, consisting of fluorescentantibody staining plus testing with the R-mix system and fibroblast tube cultures. The test set consisted of 410
archived respiratory specimens, mostly nasopharyngeal swabs, including 210 that had been positive by conventional testing for a balanced selection of common respiratory viruses. Specimens yielding discrepant results
were evaluated using a panel of respiratory virus PCR assays developed, characterized, and validated with
clinical specimens. PLx-RVP increased the total rate of detection of viruses by 35.8%, and there was a 25.7%
increase in the rate of detection of positive specimens. Reference PCR assay results corroborated the PLx-RVP
result for 54 (82%) of 66 discrepancies with conventional testing. Of the 12 specimens with discrepancies
between PLx-RVp and the reference PCRs, 6 were positive for rhinovirus by PLx-RVP and the presence of
rhinovirus was confirmed by nucleotide sequencing. The remaining six specimens included five in which the
PLx-RVP failed to detect parainfluenza virus and one in which the detection of influenza A virus by PLx-RVP
could not be confirmed by the reference PCR. Taking the results of the reference PCR assay results into
account, the sensitivities of the PLx-RVP for individual viruses ranged from 94 to 100% and the specificities
ranged from 99 to 100%. We conclude that PLx-RVP is a highly accurate system for the detection of respiratory
viruses and significantly improves the rate of detection of these viruses compared to that by conventional
virologic testing.

lecular Diagnostics (Toronto, ON, Canada). This test, which
uses the Luminex-100 or -200 flow cell instrument (12), has
been cleared by the Food and Drug Administration for use in
the United States for the simultaneous detection and identification of multiple respiratory viruses from nasopharyngeal
swab specimens from individuals with suspected respiratory
tract infection. In the present study, we have evaluated a different respiratory multiplex PCR test, the PLx MultiCode Respiratory Virus Panel (PLx-RVP), manufactured by Eragen
Biosciences, Inc. (Madison, WI). Two important characteristics of the evaluation are, first, that we have included substantial numbers of specimens containing each of the common
respiratory viruses detected by the test and, second, that we
have designed and validated PCR assays to detect each of the
respiratory viruses and used these assays to resolve discrepancies between the results of conventional testing (fluorescentantibody [FA] staining and culture) and PLx-RVP.

The rapid and accurate detection of respiratory viruses is
clinically important. Potential advantages of specific viral detection include obtaining prognostic information, limiting additional diagnostic testing, instituting appropriate infection
control precautions, and limiting unnecessary antibiotic usage.
The use of respiratory specimens for this purpose is challenging because of the broad range of pathogens that may be
present. This task is becoming even more complicated with
the recent discoveries of several new viruses in respiratory
tract samples, including human metapneumovirus (MPV)
(19), coronaviruses (CoVs) NL63 (4, 20) and HKU1 (23),
human bocavirus (3), and polyomaviruses KI (2) and WU (5).
Molecular methods offer the advantages of rapidity and the
ability to detect viruses regardless of the growth requirements
or the availability of reagents for rapid diagnostic testing. An
exciting recent advance is the development of multiplex molecular assays that allow the simultaneous detection of multiple
targets in the same reaction (12, 13, 15, 16). One such test is
the xTAG Respiratory Virus Panel, produced by Luminex Mo-

MATERIALS AND METHODS
Specimens. The specimens used to evaluate the PLx-RVP were selected from
samples submitted for respiratory virus detection to the Virology Laboratory
(VL) at St. Louis Children’s Hospital (SLCH). All types of respiratory specimens
were included, with the majority being nasopharyngeal swabs. Specimens were
mostly collected during the time period from October 2004 to May 2006, although in some cases it was necessary to collect samples outside this time period
to achieve the desired number of specimens that had been positive for specific
viruses (see below). Specimens were selected to include 30 that had been positive
by conventional testing (FA staining, when applicable, and culture) in the VL for
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5

4

3

2

1

AdV

PIV types 4a and 4b

PIV type 2

PIV types 1 and 3

RSV group B (21)

RSV group A (21)

CoV HKU1

CoV NL63 (4)

CoV 229E

CoV OC43

InfB (22)

InfA (22)

Virus assay
(reference)b

van
van
van
van
van
van

Elden
Elden
Elden
Elden
Elden
Elden

RSA-1
RSA Probe
RSA-2
RSB-1
RSB Probe
RSB-2

Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad

Hex MQA5 For
Hex MQA1 probe
Hex MQA2 probe
Hex 31 probe
Hex B/E probe
Hex A/C/D probe
Hex MQA6 Rev
Hex MQA7 Rev
Hex 31 Rev
Pent PE15841 For
Pent PE15939 RProbe
Pent PE15963 Rev

HPIV 1⫹3 For3
HPIV3MQAFor4
HPIV 1⫹3 Probe3
HPIV3MQAPro4
HPIV1⫹3 Rev7
HPIV3MQARev8
HPIV2 MQA For2
HPIV2 MQA Pro2
Para2MQAPro2b
HPIV2 MQA Rev2
HPIV2MARev2a
Para2MQARev2b
HPIV4MQAPhosFor4
HPIV4MQAPhosPro4
HPVI4MQAPhosRev4

RSV
RSV
RSV
RSV
RSV
RSV

BC OC43 N-gene For
BC OC43 N-gene probe
BC OC43 N-gene Rev
BC 229E N-gene For
BC 229E N-gene probe
BC 229E N-gene Rev
Fouchier et al. (4), set 1 For
Fouchier et al. (4), set 1 probe
Fouchier et al. (4), set 1 Rev
HKU1 N gene564 F
HKU1 N Gene588 Tpr
HKU1 N Gene 631 R

Pkz/Glxo FluAfor
Inf A R/A probe
Pkz/Glxo FluA Rev
GSK FluB for
GSK FluB Pro MGB
GSK FluB Rev4
GSK FluB Rev5

Primer/probe name

Hexon gene
Hexon gene
Hexon gene
Hexon gene
Hexon gene
Hexon gene
Hexon gene
Hexon gene
Hexon gene
Penton gene
Penton gene
Penton gene

Phosphoprotein gene

Phosphoprotein gene

L gene

N gene

N gene

N gene

N gene

N gene

N gene

Matrix gene

Matrix gene

Primer/probe target

CGCAGTGGKCTTACATGCACATC
FAM-CCGGGCTGGTGCAGTT-MGB
FAM-CGGGTCTGGTGCAGTT-MGB
FAM-CCGGTCTGGTGCAATT-MGB
FAM-GCTTCGGAGTACCT-MGB
FAM-GCCTCGGAGTACCT-MGB
CCACTGTGGGGTTTCTAAATTTGTT
ACCGTGGGGTTTCTAAACTTGTT
CCACAGTGGGATTCCTAAACTTGTT
AAACGTTCCTGCTCTCACAGATC
FAM-CAGGTGCGGCGTCT-MGB
CCCAGGGCCTTGTARACGTA

AGTGCAATMCATCTWGCRGCTGTTA
ATTATAAGTAGCAAGATGTTCATATATAGCAAA
FAM-CAAGGAGAYAATCAAGCYATA-MGB
FAM-GATGGGAGAATTCTTC-MGB
GTGATRTCTTCATAGACGTGAGTCTTT
ACCARAAGACACATCTAGATAATGCTTT
CCCAGCATCTGCGGAGAAT
FAM-AAGGAGATCATTGAGCTCT-MGB
FAM-AGGGAGATCATTGAGCTCT-MGB
AAGGCGAAGATCAAGTCCCTTT
CTACAGTCTGAAGGCGAAGATCAAG
AAGGCGAAGATCAAGCCCCTTT
CACTCAACAAATYAAAGGTTCACTTGC
FAM-ATTGAGGGCCTAATCAC-MGB
GACTCCAGGGTCCATTATTTTCA

AGATCAACTTCTGTCATCCAGCAA
FAM-CACCATCCAACGGAGCACAGGA GAT-MGB
TTCTGCACATCATAATTAGGAGTATCAAT
AAGATGCAAATCATAAATTCACAGGA
FAM-ATATGCTATGTCCAGGTTAG-MGB
TGATATCCAGCATCTTTAAGTATCTTTATAGTG

GTTGTACAGGATGTGGGA
FAM-CTGGATACCAGGAGTT-MGB
CGAACTTAGTCGTCATGT
TGCATTTTTATTATCTTGGC
FAM-CTGTTGATGGTGCTAAA-MGB
TGAATTCTTGCGCCTAAC
TGTCAACGAGGTTTTGCATTAAAT
FAM-ATGCGTTTAGCGCATGA-MGB
ACTGGCCTACCATTGTGTGTAAGA
GGCTCAGGAAGGTCTGCTTCTA
FAM-AGTCGACCAGGTTCACGTT-MGB
CGATTATTGGGTCCACGTGAT

AAGACCAATCCTGTCACCTCTGA
VIC-TTCACGCTCACCGT-MGB
CAAAGCGTCTACGCTGCAGTCC
GAGACACAATTGCCTACCTGCTT
FAM-GCAAAGCAGAACTAGC-MGB
TCTTTCCCACCGAACCAACA
TCTTTCCCACCAAACCAACA

Sequence (5⬘–3⬘)

Species A ⫽ 34, species B ⫽ 11,
species C ⫽ 9, species D ⫽ 12,
species E ⫽ 5

356

1,455

PIV type 1 ⫽ 16, PIV type 3 ⫽ 258

ND

ND

⬍10

⬍10

⬍10

⬍10

1

5

Analytical sensitivity (no. of copies
per reaction)
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BCRABLfor
BCRABLprobe
BCRABLrev
BCR/ABL
8

ND, not determined; NCR, noncoding region.
The source of the PCR assay is shown by the reference citation. In some instances, the primer and probe sequences listed represent modifications of the published sequences. If no reference citation is provided, the
assay was developed for this study. The BCR/ABL primers and probe are from Asuragen, Inc.
c
Two clade A viruses were evaluated. The LOD for rhinovirus type 2, the sequence of which matches the sequences of the primers and probes, was two copies. The LOD for rhinovirus type 33, the sequence of which
has one mismatch in the forward primer, was 25 copies.
d
Locked nucleic acid.
b

a

ND
CCGCTGACCATCAATAAGGAA
NED-AGCCCTTCAGCGGC-MGB
TGAGGCTCAAAGTCAGATGCTACT

Clade A ⫽ 2-25,c clade B ⫽ 13,
clade C ⫽ 13
Cy⫹dAGCC⫹dTGCGTGGC
FAM-TCCTCCGGCCCCTGAATGYGGC-3BHQ_1
GAAACACGGACACCCAAAGTA
RV (10)
7

CDC Rhino F
CDC Rhino P
CDC Rhino R

MPV (11)
6

Forward
NLN1MGB
NLN2MGB
Reverse

5⬘ NCR

MPV-B ⫽ 9

MULTIPLEX RESPIRATORY VIRUS PANEL AND REAL-TIME PCRs

2389

the following viruses: influenza A virus (InfA), influenza B virus (InfB), respiratory syncytial virus (RSV), adenovirus (AdV), and rhinovirus (RV). Because
parainfluenza viruses (PIVs) are not routinely typed in the VL, 60 specimens
positive for PIV were selected to try to achieve representation of each PIV type.
In addition, a total of 198 specimens that had been negative for respiratory
viruses in the VL were included. Nucleic acid extracts were prepared using a
Bio-Robot M48 apparatus with the MagAttract virus mini M48 kit (Qiagen Inc.,
Valencia, CA) from 200-l aliquots of supernatant prepared from specimen
transport medium, eluted in 100 l, and stored at ⫺70°C. These extracts were
used in the PLx-RVP and the reference PCR assays developed in our laboratory
(see below).
In addition to the respiratory specimens used to evaluate the PLx-RVP, other
respiratory specimens submitted to the VL were used to validate the respiratory
virus PCR assays developed in our research and development laboratory at
Washington University to serve as reference assays (see below). For those viruses
that are included in the panel of fluorescent-antibody stains used in the VL (InfA
and -B, RSV, PIV types 1 to 3, AdV), validation specimens were selected to
include some that were positive by direct FA staining of the specimen and some
that were negative by FA staining but positive by culture. For influenza virus,
negative specimens included some that had been obtained during the winter and
others that had been obtained during summer months, when no influenza viruses
were detected in the VL. For RV, the specimens selected included some that had
been found to be positive for RV by other molecular assays being evaluated in
the laboratory. The results of previous molecular tests were not known by
personnel performing the validation testing. The human MPV assay was validated by comparing its results to those obtained with different PCR assays that
had been developed by one of the authors (1). The targets for these assays were
a segment of the N gene of genotype A and a segment of the P gene of genotype
B. The MPV assay was also validated by comparing its results to those of FA
staining performed in the VL using a commercially available fluorescein-labeled
antibody (Diagnostic Hybrids, Athens, OH).
Virology Laboratory procedures. Respiratory specimens submitted to the VL
were processed by low-speed centrifugation. The cell pellet was spotted on glass
microscope slides that were stained using Simulfluor reagents (Diagnostic Hybrids) and visualized under a fluorescence microscope to detect InfA and -B,
RSV, PIV types 1 to 3, and AdV. Virus culture was performed using the R-mix
system (Diagnostic Hybrids). The cells were stained approximately 16 and 40 h
after inoculation using the same Simulfluor reagents. In addition, a roller tube of
MRC-5 human fibroblast cells was inoculated and incubated for 10 to 14 days to
detect rhinovirus by the appearance of the characteristic cytopathic effect.
PLx-RVP. The MultiCode-PLx platform, manufactured by Eragen Biosciences,
Inc., utilizes multiplex PCR to amplify target sequences, followed by interrogation of the resulting amplicons via target-specific extension and, finally, solidphase hybridization and detection (7). The assay is driven by a proprietary novel
base pair that is used for both site-specific labeling and room temperature
capture of the extension products. The assay is read on the Luminex-100 instrument, and the raw data are analyzed using proprietary software. A positive signal
is typically defined by reporter values that are greater than 6 standard deviations
above the background signals observed when target nucleic acid is absent (see
Table S1 in the supplemental material).
The PLx-RVP detects the presence of nucleic acids from the following viruses:
InfA and -B; RSV types A and B; PIV types 1, 2, 3, 4a, and 4b; RV; human CoVs
OC43, 229E, and NL63; MPV; and AdV species B, C, and E. The specific
procedures for performing the PLx-RVP have been described previously (13,
15). Testing with the PLx-RVP was performed at the Eragen Biosciences laboratory in Madison, WI, using nucleic acid extracts prepared from specimens at
Washington University, as described above. All Eragen Biosciences personnel
involved in this testing were blinded to the results obtained in the VL. The results
were sent to Washington University for analysis. The PLx-RVP was classified as
being for research use only at the time that testing was performed.
Respiratory virus PCR assays. Because it was anticipated that there might be
discrepancies between the results of PLx-RVP and conventional testing, realtime PCR assays for each respiratory virus were established to serve as reference
assays for the purpose of adjudicating discrepancies. The primers and probes
used for some of these assays were derived from the literature, and others were
based on analysis of sequences available in public databases. The primer and
probe sequences are shown in Table 1. Most probes included minor groove
binder (MGB) moieties to take advantage of relatively short conserved target
sequences. Primers and probes were ordered from Applied Biosystems (ABI;
Foster City, CA). The samples were initially evaluated in singleplex assays, but as
development progressed, primer/probe sets from the singleplex assays were combined with other primer/probe sets and the samples were tested in multiplex
assays, as shown in Table 1. Validation was performed by use of the same assay
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TABLE 2. Validation of reference real-time respiratory virus PCR assaysa
No. of specimens with pos PCR VL result/no. tested (% PCR pos)
Virus target(s)

FA staining
pos

FA staining neg,
culture pos

FA staining neg,
culture neg

1b
1b
3
4
5
6
6

Influenza A virus
Influenza B virus
Respiratory syncytial virus
Parainfluenza virus
Adenovirus
Human metapneumovirus
Rhinovirus

30/30 (100)
31/31 (100)
30/30 (100)
16/16 (100)
3/3 (100)
16/16 (100)
NAd

30/30 (100)
27/30 (90)
9/9 (100)
8/11 (73)
26/26 (100)
NAc
27/27 (100)d

1/152 (0.7)
0/152
6/39 (15)
0/10
0/33
7/104 (7)c
26/66 (39)d

a

NA, not applicable; pos, positive; neg, negative.
The influenza virus multiplex assay detects both influenza A and B viruses and can distinguish between them with different probe labels.
No cultures were performed for human metapneumovirus. Each of the seven specimens that were positive by reference PCR was also positive by other PCR
assays (1).
d
No FA staining was performed.
b
c

configuration that was used to test specimens for comparison with the PLx-RVP
results. All assays except the RV and MPV assays included an amplification
control in each reaction. For RNA viruses, this consisted of 300 copies per
reaction mixture of BCR/ABL RNA obtained from Asuragen, Inc. (Austin, TX),
plus BCR/ABL primers and probes, as shown in Table 1. The BCR/ABL probe
was labeled with NED (Applied Biosystems) or VIC (Applera) to allow its signal
to be distinguished from that of the virus probes, which were labeled with
6-carboxyfluorescein (FAM) for all probes except the InfA probe, which was
labeled with VIC. For the adenovirus assays, the amplification control consisted
of a proprietary internal positive control purchased from Applied Biosystems.
The probe used to detect the DNA amplification control was labeled with VIC.
All assays except the adenovirus assay were set up using the Qiagen QuantiTect
multiplex reverse transcription-PCR (RT-PCR) mix with a reaction volume of
50 l. The adenovirus assay used the ABI universal master mix. All assays were
run on an ABI 7500 thermal cycler with the following parameters: 50°C for 20
min, followed by 95°C for 15 min and then 45 cycles of 94°C for 45 s and 60°C for
1 min. Before being used to resolve discrepancies, the Washington University
assays were validated using the validation panels described above.
Rhinovirus typing. Typing of RV was done by analyzing a 260-bp variable
sequence of the 5⬘ noncoding region of the RV genome (9). Briefly, the target
sequences were amplified from total cDNA by seminested PCR. The PCR
fragment was purified and then cloned into a plasmid vector. For each sample,
three or more plasmids were then retrieved, purified, and sequenced. The resultant sequences were compared with the homologous sequences of 101 classical serotypes and the recently identified new strains (prefixed with W) using
phylogenetic tree reconstruction and bootstrap analysis with ClustalX software.
The RV in each specimen was assigned the serotype or strain to which it
clustered within the phylogenetic tree with a significant bootstrap value (⬎50%).
All assigned serotypes/strains in this study had 96 to 100% sequence identities
with the respective reference serotypes/strains. In contrast, if a new sequence did
not cluster with one of the reference sequences in the phylogenetic tree and had
⬎8% pairwise nucleotide divergence from the nearest reference serotype/strain,
it was designated a new strain.
Positive controls and LODs. Formal limits of detection (LODs) were determined for each of the reference PCR assays except the RSV and MPV type A
(MPV-A) assays. For the InfA and -B assays, the positive controls for the assays,
which were also used to determine the LODs, were purchased from Advanced
Biotechnologies, Inc. (Columbia, MD), and consisted of purified virus preparations (InfA/PR/8/34/H1N1 and InfB/Lee/40) that had been quantified by determination of particle counts. Viral RNA was extracted from a known amount of
virus with a MagNa Pure compact apparatus (Roche Diagnostics, Indianapolis,
IN) using the MagNa Pure LC total nucleic acid isolation kit. For the remaining
viruses, a segment of approximately 1,000 bp surrounding the PCR product was
cloned into plasmid pCR II-TOPO (Invitrogen Corp., Carlsbad, CA). For rhinovirus, four different rhinovirues were selected to determine the LODs for each
clade, including rhinoviruses 2 and 33 for clade A, rhinovirus 17 for clade B, and
rhinovirus QPM for clade C. All these rhinoviruses except for QPM were obtained from ATCC; QPM was an isolate from our laboratory identified by
nucleotide sequencing of the 5⬘ noncoding region of the genome. As determined
by sequencing of the cloned segment in our laboratory, rhinoviruses 17 and 33
each have one mismatch with the forward primer and rhinoviruses 2 and QPM
each match the primer and probe sequences completely. RNA transcripts were

created using SP6 or T7 RNA polymerase and were quantitated using a spectrophotometer (NanoDrop Technologies, Wilmington, DE) or a Cubitt fluorometer (Invitrogen). The transcripts were stored at ⫺70°C and diluted in 10-fold
dilutions in RNase-free water immediately before use. For the adenovirus assays,
plasmid DNA was purified and the copy number was calculated using a Nanodrop spectrophotometer and the known molecular weight of the plasmid and
insert. The AdVs used were AdV A (type 31), AdV B (type 3), AdV C (type 5),
AdV D (type 19), and AdV E (type 4). The type 31 strain was provided by
Gregory Gray, University of Iowa Center for Emerging Infectious Diseases; the
other strains were isolates from the SLCH VL that were typed in Gregory Gray’s
laboratory by sequencing a segment of the hexon gene (6). The LODs for each
assay were determined by testing six replicates of a series of dilutions and
calculating by probit analysis the number of copies that could be detected with
95% confidence (SPSS software, version 16; SPSS Inc. Chicago, IL). The LODs
are shown in Table 1.

RESULTS
Validation of the reference PCR assays. The reference PCR
assays were validated by testing total nucleic acid extracts from
patient specimens that had been analyzed in the VL. The
results of the validation testing are shown in Table 2. The
reference PCR assays gave positive results for all specimens
that were positive by FA staining. They were also positive for
all specimens that were positive by culture with a negative FA
staining result except three specimens that were culture positive for InfB and three specimens that were culture positive for
PIV. For RV, no FA staining was performed in the VL, but the
reference RV PCR was positive for all specimens that had
been culture positive for RV. For InfA and -B, PIV, and AdV,
the reference PCRs were negative for all specimens that had
been negative by conventional testing, with the exception of
one specimen that was positive for InfA. For RSV, the reference PCR was positive for 15% of specimens that were negative by FA staining and culture, and for RV, the reference PCR
was positive for 39% of specimens that had been negative for
rhinovirus by culture. For MPV, the reference PCR was positive for all 16 specimens that were positive by FA staining and
also for 7 (7%) of the 104 specimens that were negative by FA
staining. The MPV specimens were also tested by M- and
P-gene PCRs. The reference PCR was positive for 23 of 24
specimens that were positive by the M- and P-gene PCRs and
was negative for all 96 specimens that were negative by the Mand P-gene PCR assays. The 23 specimens that were positive
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TABLE 3. PLx-RVP compared to conventional virus testing using fluorescent-antibody staining and culture
Virus

PLx-RVP
result

Conventional testing result
(no. of specimens)a
Positive

Negative

Sensitivityb
(%)

Specificityc
(%)

PPVd
(%)

NPVe
(%)

99

Influenza A virus

Positive
Negative

29
3

12
365

91

97

71

Influenza B virus

Positive
Negative

29
1

0
379

97

100

100

Respiratory syncytial virus

Positive
Negative
Equivocal

33
0
0

5
370
1

100

99

87

100

Parainfluenza virus

Positive
Negative
Equivocal

50
6
4

3
343
3

83

99

94

98

Rhinovirus

Positive
Negative
Equivocal

30
0
0

33
345
1

100

91

48

100

Adenovirus

Positive
Negative
Equivocal

30
0
0

6
371
2

100

98

83

100

99.7

Positive by either FA staining or culture. No FA staining was performed for rhinovirus.
In calculations of sensitivity, a result of “equivocal” was included in the calculation and was counted as a false-negative result.
c
In calculations of specificity, results of “equivocal” were not considered false positive and therefore were not included in the calculation.
d
PPV, positive predictive value.
e
NPV, negative predictive value.
b

by the reference PCR also included all 16 that were positive by
FA staining.
Comparison of Multicode-PLx Respiratory Virus Panel with
Virology Laboratory results. A total of 410 specimens that had
been submitted to the VL were tested using the PLx-RVP. One
sample that was negative in the VL had a failed internal control in the PLx-RVP, despite repeat testing, and was excluded
from analysis. In all, the PLx-RVP detected 292 viruses in 264
specimens, whereas conventional testing detected 215 viruses
in 210 specimens. This represents a 35.8% increase in yield in
viruses and a 25.7% increase in positive specimens. The increased yield was accounted for primarily by the greatly enhanced detection of RV plus the detection of MPV and CoVs,
which were not detected by conventional testing. The comparison of the PLx-RVP results with those of conventional testing
are summarized in Table 3 for all viruses except CoV and
MPV, which are not included because these viruses could not
be detected by conventional testing. The sensitivity of the PLxRVP for specific viruses ranged from 83% (PIV) to 100%
(RSV, AdV, and RV). The specificity ranged from 91% (RV)
to 100% (InfB). Of the 38 RSVs detected by the PLx-RVP, 25
were identified as group A and 13 as group B. Of the 53 PIVs
identified by the PLx-RVP, 28 were identified as type 1, 13 as
type 2, 9 as type 3, and 3 as type 4b. Of the total of 10 PIVs that
were detected by conventional testing but not by the PLx-RVP,
4 were PIV type 1, 2 were PIV type 2, 2 were PIV type 3, 1 was
PIV type 4, and 1 was not typed. Of the 36 AdVs detected, 30
were group C and 6 were group B. In addition, the PLx-RVP
detected MPV in 17 specimens and CoV in 15 specimens (for
NL63, n ⫽ 8; for OC43, n ⫽ 7). There were a total of 27 mixed
virus infections detected by the PLx-RVP (Table 4). Two vi-

ruses were detected in 26 specimens, and 3 viruses were detected in 1 specimen.
Reference PCR assays. The reference PCR assays were performed with all specimens that were positive either by the
PLx-RVP or by conventional testing in the VL and also with a
sample of approximately 25% of the specimens that were negative for any viruses by both the PLx-RVP and by FA staining
and culture in the VL. The results of this testing are shown in
Table 5. A total of 637 reference PCR tests were performed.
Excluding nine specimens for which the PLx-RVP result was
equivocal and one specimen for which the reference PCR

TABLE 4. Multiple virus infections detected by the PLx-RVP
No. (%) of multiple virus
infections detecteda
Virus

Influenza A virus
Influenza B virus
Respiratory syncytial virus
Parainfluenza virus
Rhinovirus
Adenovirus
Metapneumovirus
Coronavirus

Total
detected

Detected as
component of
mixed infection

41
29
38
53
63
36
17
15

4 (10)
0
9 (24)
8 (15)
13 (21)
9 (25)
4 (24)
8 (57)

a
The numbers of mixed infections were as follows: PIV and RV, 6; AdV
and RV, 4; RSV and OC43, 4; RSV and AdV, 2; AdV and MPV, 2; InfA and
AdV, 1; InfA and RSV, 1; InfA and OC43, 1; RSV and PIV, 1; RSV and
NL63, 1; RV and MPV, 1; RV and NL63, 1; MPV and NL63, 1; InfA, PIV,
and RV, 1.
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TABLE 5. Results of reference PCR assays compared to results of PLx-RVP and conventional viral testing
No. of specimens
Virus

Result of PLx-RVP/result
of conventional testinga

With the indicated result
by reference PCR

Evaluated by
reference PCR

Positive

Negative

Pos/Pos
Pos/Neg
Neg/Pos
Neg/Neg

29
11b
3
64

29
10
0
0

0
1
3
64

Influenza B virus

Pos/Pos
Pos/Neg
Neg/Pos
Neg/Neg

29
0
1
73

29
0
0
1

0
0
1
72

Respiratory syncytial virus

Pos/Pos
Pos/Neg
Neg/Pos
Neg/Neg

33
5
0
30

33
5
0
0

0
0
0
30

Parainfluenza virus

Pos/Pos
Pos/Neg
Neg/Pos
Neg/Neg
Eq/Pos
Eq/Neg

49b
3
6
32c
4
3

49
3
5
0
4
0

0
0
1
32
0
3

Rhinovirus

Pos/Pos
Pos/Neg
Neg/Pos
Neg/Neg

29b
32b
0
33

29
26
0
0

0
6
0
33

Adenovirus

Pos/Pos
Pos/Neg
Neg/Pos
Neg/Neg
Eq/Neg

29b
5b
0
33
2

29
5
0
0
2

0
0
0
33
0

Coronavirus

Pos/ND
Neg/ND

15
33

14c
0

0
33

Metapneumovirus

Pos/ND
Neg/ND

17
34

17
0

0
34

a
b
c

Pos, positive; Neg, negative; ND, not determined; Eq, equivocal.
One specimen was not available for reference PCR testing.
The reference PCR result for one specimen was equivocal.

result was equivocal, the results of the reference PCR assays
were in agreement with the PLx-RVP result for 614 (97.9%) of
the 627 tests performed. There were 66 discrepancies between
PLx-RVP and conventional testing. Of these, the reference
PCR results were in agreement with the PLx-RVP result for 54
(82%). The 12 discrepancies were the following: 1 specimen
that was positive for InfA by the PLx-RVP, negative in the VL,
and negative by the reference InfA PCR; 5 specimens that
were negative for PIV by the PLx-RVP, positive in the VL, and
positive by the reference PCR; and 6 specimens that were
positive for RV by the PLx-RVP, negative in the VL, and
negative by the reference RV PCR.
Rhinovirus typing. Rhinovirus molecular typing was performed with a total of 32 specimens that had been positive by
the PLx-RVP, including all 6 that were negative by the reference PCR. RV RNA was detected and the 260-base 5⬘ noncoding region sequence was determined in each of these spec-

imens. The RV types of the six discrepant specimens were 51
(n ⫽ 2), 30, 78, W12, and W23. The RV types in the remaining
specimens were 30 (n ⫽ 1), 49 (n ⫽ 2), 51 (n ⫽ 6), 53 (n ⫽ 1),
57 (n ⫽ 1), 78 (n ⫽ 1), 80 (n ⫽ 1), 96 (n ⫽ 1), W10 (n ⫽ 3),
W17 (n ⫽ 1), W23 (n ⫽ 2), W28 (n ⫽ 1), W32 (n ⫽ 1), W38
(n ⫽ 1), W39 (n ⫽ 1), W41 (n ⫽ 1), and W42 (n ⫽ 1). The
strains with the prefix “W” are new strains that are different
from the 101 classical serotypes. All eight classical serotypes
(serotypes 30, 49, 51, 53, 57, 78, 80, and 96) are in clade A.
Analysis of the sequences of the 420-base VP4/VP2 region of
the new strains showed that types W10, W12, W17, W23, W32,
W38, W39, W41, and W42 are in clade C and that type W28 is
in clade A. Strains W10, W12, W17, W23, W28, W32, and W38
have previously been reported to be detected in infants with
cold symptoms in Madison, WI (9). Strains W39 and W41
resemble the new RV strains described by Tapparel et al. in
association with respiratory infection in Switzerland (18).
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TABLE 6. Comparisons of PLx-RVP and conventional viral detection to reference PCR assay detection
No. of specimens positive or negative/total no. tested (%)
Test system

Influenza A virus
Influenza A virus
Influenza B virus
Influenza B virus
Respiratory syncytial virus
Respiratory syncytial virus
Parainfluenza virus
Parainfluenza virus
Rhinovirus
Rhinovirus
Adenovirus
Adenovirus
Human metapneumovirus
Coronaviruses

PLx-RVP
Conventional
PLx-RVP
Conventional
PLx-RVP
Conventional
PLx-RVP
Conventional
PLx-RVP
Conventional
PLx-RVP
Conventional
PLx-RVP
PLx-RVP

a

Sensitivitya

Specificitya

Positive predictive
value

Negative predictive
value

39/39 (100)
29/39 (74)
29/30 (97)
29/30 (97)
38/38 (100)
33/38 (87)
52/61 (95)
58/61 (95)
55/55 (100)
29/55 (53)
34/36 (94)
29/34 (85)
17/17 (100)
14/14 (100)

67/68 (99)
65/68 (96)
73/73 (100)
72/73 (99)
30/30 (100)
30/30 (100)
33/33 (100)
35/36 (97)
33/39 (85)
39/39 (100)
33/33 (100)
33/33 (100)
34/34 (100)
33/33 (100)

39/40 (98)
29/32 (91)
29/29 (100)
29/30 (97)
38/38 (100)
33/33 (100)
52/52 (100)
58/59 (98)
55/61 (90)
29/29 (100)
34/34 (100)
29/29 (100)
17/17 (100)
14/14 (100)

67/67 (100)
64/75 (87)
73/74 (99)
72/73 (99)
30/30 (100)
30/35 (86)
33/38 (87)
35/38 (92)
33/33 (100)
39/65 (60)
33/33 (100)
33/38 (87)
34/34 (100)
33/33 (100)

Equivocal results are included for calculations of sensitivity but excluded for calculations of specificity.

Strain W42 matches isolate Resp_3898 reported in GenBank
(accession number GQ476669).
Recalculated test parameters. In order to calculate more
meaningful test parameters, the sensitivity, specificity, and positive and negative predictive values were recalculated for the
PLx-RVP and for conventional virus testing using the results of
the reference PCR assays as the standard for comparison. The
recalculated test parameters are shown in Table 6. The PLxRVP was more sensitive than conventional testing for all viruses except InfB (equal sensitivity) and PIV. The increased
sensitivity of the PLx-RVP for rhinoviruses was especially notable. The specificity of the PLx-RVP was between 99 and
100% for all viruses except rhinovirus, for which it was 85%. If
the six specimens that were negative for RV in the reference
PCR assay but that were shown to contain RV sequences by
the molecular typing assay are considered to have been truly
positive for RV rather than negative, the adjusted specificity
increases to 100%.
DISCUSSION
The newly developed multiplex molecular assays to detect
respiratory viruses (12, 13, 15, 16) are a major step forward in
diagnostic virology. In the present study, we evaluated one
such assay, the PLx-RVP, by comparing it to conventional
virologic testing, consisting of FA staining and culture as performed in a routine diagnostic virology laboratory. We used
laboratory-developed PCR assays as the reference method to
resolve discrepancies between the two approaches. We found
that the multiplex method achieved a 35.3% increase in the
detection of respiratory viruses. The increased yield was largely
accounted for by a very substantial increase in the rate of
detection of RV by the PLx-RVP. The other large contribution
was the detection of MPV and CoV, viruses that were not
detected by the conventional methods in use in the VL at the
time that the study was performed.
An alpha prototype version of the PLx-RVP was evaluated
in a clinical laboratory setting by Nolte et al. (15). In that
evaluation, the comparative test methods were direct fluores-

cent-antibody staining and shell vial culture. Singleplex PCR
assays were used to confirm the presence of viruses (RV, MPV,
CoV, and PIV types 4a and 4b) that were not detected by the
methods used in the clinical laboratory. The PLx-RVP detected 53% more viruses than the comparative methods, with
the results for 90% of the discrepancies being confirmed by
singleplex PCRs. A limitation of the study is that aside from
influenza A virus, which was detected in 78 samples by one or
both methods, the number of other viruses detected was relatively small, ranging from 1 to 16. Reports by Lee et al. (8) and
Marshall et al. (13) used earlier versions of the assay and
evaluated relatively small numbers of individual respiratory
viruses. The present evaluation extends the results of the previous studies by using an evaluation panel that included a
substantially larger number of specimens containing each of
the viruses that can be detected by the PLx-RVP. Specifically,
the evaluation panel included at least 30 of each of the viruses
that could be detected in the clinical VL. Although they were
not specifically selected, there were also 17 samples containing
MPV and 15 containing human CoVs. The results indicate that
the PLx-RVP is at least as sensitive as conventional methods
for the detection of each of these viruses.
Because we anticipated that the PLx-RVP would be positive
for some specimens that were negative by conventional testing,
we placed a high priority on establishing comparative molecular assays that could be used to adjudicate discrepancies. The
molecular assays used for adjudication were, in some cases,
based on previously published assays or, in other cases, were
developed using publically available sequence data. With the
exception of the RV and MPV assays, each assay had an
internal amplification control, and all assays with the exception
of the RSV and MPV-A assays had a defined analytic limit of
detection, defined as the minimum number of nucleic acid
copies that could be detected by the assay with 95% confidence
on the basis of probit analysis. In addition, each assay (except
that for CoV) was validated using a separate panel of specimens that had been shown to contain the target analyte by
conventional testing. For each of the viruses for which direct
FA staining was being performed in the Virology Laboratory,
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where the specimens were originally tested, some of the validation samples were selected because they had been negative
by FA staining and positive by culture, suggesting the presence
of a low level of virus. The reference assays corroborated the
findings of the PLx-RVP in almost 98% of the samples which
had yielded discrepancies between the PLx-RVP and conventional testing.
The two viruses which were associated with the largest numbers of discrepancies were RV and PIV. As was seen in the
other evaluations (8, 13, 15), the PLx-RVP detected many
more RVs than conventional testing. The presence of RV was
confirmed in the large majority of the discrepant specimens by
the reference PCR assay, supporting the enhanced sensitivity
of PLx-RVP for RV. Of the six specimens that were positive by
PLx-RVP and negative by the reference PCR, further molecular testing based on amplification and sequencing of a segment of the 5⬘ noncoding region of the RV genome revealed
RV in all six. Thus, although the adjusted specificity of the
PLx-RVP for rhinovirus, on the basis of the results of the
reference PCR, was calculated to be 85%, it should be considered to be 100%, since all six of the discrepant samples were
shown by an independent molecular method to have RV RNA.
It is notable that the sensitivity of the PLx-RVP appears to
exceed that of the reference PCR, even though the LODs
determined for the reference PCR were very low, ranging from
2 to 25 copies per reaction mixture, depending on whether the
sequence of the serotype used to evaluate the LOD matched or
had a mismatch with the primers and probes of that assay. For
PIV, the PLx-RVP was either negative or equivocal for 10 of
the 60 samples in which PIV had been detected by conventional
testing. The reference PCR assay confirmed the detection of PIV
in 9 of the 10 samples, suggesting that the PLx-RVP was truly less
sensitive than conventional testing for the detection of PIV. PIV
types 1 to 4 were represented among the samples in which PIV
was missed by PLx-RVP, suggesting that the decreased sensitivity
of PLx-RVP extends across all PIV types.
In summary, with the exception of PIV, the PLx-RVP
showed excellent sensitivity and specificity across the full range
of viruses that it has the ability to detect, measured against
conventional virologic testing, with discrepancies being adjudicated with highly sensitivity reference PCR assays. The excellent sensitivity of the assay for rhinovirus is a notable
strength of the assay, particularly in the face of mounting
evidence for the clinical significance of rhinoviruses (14, 17).
This study adds to the body of evidence that respiratory virus
multiplex PCR assays can enhance the detection of respiratory
viruses. Further studies are now required to determine the
clinical utility and cost-effectiveness of such tests in the clinical
arena.
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